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Abstract 
Lymphocyte-rich classical Hodgkin lymphoma 
accounts for a small fraction of all Hodgkin 
lymphomas.  
Lymphocyte-rich classical Hodgkin lymphoma is a 
rare variant of classical Hodgkin lymphoma which 
resembles nodular lymphocyte predominance 
Hodgkin lymphoma, in terms of nodular growth and 
lymphocyte-richness, and mimics cHL, in terms of 
the immunophenotype of the tumour cells. 
Lymphocyte-rich classical Hodgkin lymphoma 
tumour cells have lost the B-cell phenotype, but 
express CD30 and the B-cell transcription program. 
As regards to genetics and cytogenetics findings 
please refer to the general features described in the 
CARDS related to nodular lymphocyte 
predominance Hodgkin lymphoma and classical 
Hodgkin lymphoma. 
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Identity 
Other names 
Nodular lymphocyte-rich classical Hodgkin 
lymphoma 
LRCHL 
Nodular lymphocyte-rich classical Hodgkin disease 
Clinics and pathology 
Disease 
Hodgkin lymphoma (HL) has been classified into 
classical HL (cHL) (Stein et al., 2008), which 
accounts for 95% of all cases, and the less common 
nodular lymphocyte predominant HL (NLPHL) 
(Poppema et al., 2008). A variant of cHL which 
resembles NLPHL, in terms of nodular growth and 
lymphocyte-richness, and mimics cHL, in terms of 
the immunophenotype of the tumour cells, was 
originally designated nodular lymphocyte-rich 
classic Hodgkin disease (Anagnostopoulos et al. 
2000), now called lymphocyte-rich cHL (LRCHL). 
LRCHL displays histologic and clinical features 
intermediate between those of cHL and NLPHL 
(Nam-Cha et al., 2009; Anagnostopoulos et al., 
2008; Swerdlow et al., 2016). 
Phenotype/cell stem origin 
Cell origin: LRCHL involves a clonal expansion of 
B lymphocytes which mimic those observed in the 
outer zone of germinal centers of lymphoid follicles 
(Nam-Cha et al., 2009). Tumour cells have partly 
lost the B-cell phenotype and coexpress CD30 and 
the B-cell transcription program. 
Phenotype: The tumour cell phenotype, which is 
characterized by the expression of CD30, also shows 
the expression of CD20 and B-cell transcription 
factors.  
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The phenotype is the following (Nam-Cha et al., 
2009): 
MUM1/IRF4 + (100%) 
PAX5 + (94%) 
BOB1 + (62%) 
CD15+ (56%) 
OCT2 + (56%) 
OCT1 + (50%) 
BCL6 + (36%) 
CD20+ (31%) 
 Cell microenvironment 
LRCHL tumour cells reside in a microenvironment 
resembling expanded mantle zones, where numerous 
small B lymphocytes displaying a mantle cell 
phenotype (IgD+, CD20+) are admixed with 
meshworks of dendritic reticulum cells (CD21+, 
CD23+). LRCHL tumour cells are rosetted by 
CD4+, PD1+ T cells. 
Epidemiology 
LRCHL accounts for only a small fraction (3% to 
5%) of all HLs (Younes et al., 2014), in similar 
frequency to NLPHL. The median age is similar to 
NLPHL and significantly higher than in other 
subtypes of cHL. There is a male predominance 
(Shimabukuro-Vornhagen, et al., 2005). 
Pathology 
Among the four histological subtypes of cHL, 
nodular sclerosis and mixed cellularity are the most  
common subtypes, whereas the lymphocyte-
depleted and lymphocyte-rich subtypes are the less 
common (Stein et al., 2008). 
LRCHL exhibits a nodular growth pattern.  
The nodules are composed of small lymphocytes and 
may harbour germinal centers that are usually 
eccentrically located and relatively small or 
regressed.  
The neoplastic cells, the Hodgkin Reed-Sternberg 
(HRS) cells, are predominantly found within the 
nodules, but consistently outside of the germinal 
centers.  
The HRS cells show broad morphologic spectrum: a 
proportion of the HRS cells may resemble 
lymphocyte predominant (LP) cells or mononuclear 
lacunar cells.  
However, the demonstration of an 
immunophenotype typical for classical HRS cells 




At variance with NLPHL the neoplastic cells in 
LRCHL appear to be permissive for an EBV 
infection. EBV infection is observed in LRCHL 
tumour cells less frequently than in mixed cellularity 
cHL but more frequently than in nodular sclerosis 
cHL (Carbone et al., 2016). 
 
figure 1. The Figure shows that LRCHL displays histologic and phenotypic features intermediate between those of NLPHL and 
cHL. LRCHL may hypothetically be an early presentation of cHL in which tumour cells have lost the B-cell phenotype but 
coexpress CD30 and the B-cell transcription program (Younes et al., 2014). 
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It seems appropriate to mention here that the 
virologic characteristics of HL of the general 
population vary according to the 
immunocompetence status of the host and cHL 
subtype (IARC, 2012) as follows: 
cHL of the general population 
- Nodular sclerosis cHL, usually EBV negative 
- Mixed cellularity cHL, usually EBV positive 
- LRCHL, variably EBV positive 
- Lymphocyte depletion cHL, variably EBV positive 
- NLPHL usually EBV negative 
Evolution 
Clinically, patients with NLPHL and LRCHL show 
similar disease presentation but differ in the 
frequency of multiple relapses and prognosis after 
relapse. Patients with NLPHL and LRCHL differ 
from patients with cHL with nodular sclerosis or 
mixed cellularity, as they present with an earlier 
disease stage (Anagnostopoulos et al. 2000). 
Prognosis 
Most LRCHLs have a better prognosis than do other 
cHLs. 
Genetics 
See the pertinent sections within the CARDS 
describing the general features of NLPHL and cHL 
(Küppers, 2011; Carbone and Gloghini, 2016; 
Gloghini and Carbone, 2016). 
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